Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor...
Astellas initiates trial to evaluate VMS therapy fezolinetant
Astellas Pharma has initiated the SKYLIGHT 1 Phase III trial to evaluate fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS), hot flashes, and night sweats associated with the menopause.
Lilly reports improved survival in Verzenio’s MONARCH 2 trial
Eli Lilly has reported positive findings from the Phase III MONARCH 2 clinical trial of Verzenio (abemaciclib) with fulvestrant to treat advanced or metastatic breast cancer.
Keytruda improves response in late-stage breast cancer study
Merck has reported positive results from the Phase III KEYNOTE-522 clinical trial of Keytruda in combination with chemotherapy for the treatment of triple-negative breast cancer (TNBC).
Vyleesi (bremelanotide) for the Treatment of Hypoactive Sexual Desire Disorder
Vyleesi™ (bremelanotide) is a peptide drug indicated for treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
Myovant’s relugolix meets Phase III endpoints for uterine fibroids
Myovant Sciences has reported positive results from the Phase III LIBERTY 2 study of its relugolix combination therapy for the treatment of uterine fibroids.
GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
GlaxoSmithKline (GSK) has announced promising data for its Zejula (niraparib) drug as a maintenance therapy in the Phase III PRIMA clinical trial involving ovarian cancer patients.
Piqray (alpelisib) for the Treatment of Advanced Breast Cancer
Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR) positive or HER2-negative advanced breast cancer with PIK3CA mutation in men and post-menopausal women.
Eisai and MedSIR study Halaven in breast cancer patients
Eisai Europe has partnered with MedSIR to assess Halaven (eribulin) in the REVERT clinical study, which involves metastatic breast cancer patients.
Daiichi Sankyo-AstraZeneca’s breast cancer therapy clears trial
Daiichi Sankyo and AstraZeneca have reported positive findings from the Phase II DESTINY-Breast01 clinical trial of trastuzumab deruxtecan (DS-8201).
Nerlynx (neratinib) for the Treatment of Breast Cancer
Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer.